AVANOS MEDICAL (NYSE:AVNS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.
A number of other brokerages also recently issued reports on AVNS. Wall Street Zen downgraded shares of AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Zacks Research upgraded shares of AVANOS MEDICAL to a "hold" rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Reduce".
View Our Latest Stock Report on AVANOS MEDICAL
AVANOS MEDICAL Trading Up 0.6%
AVNS traded up $0.06 during trading on Tuesday, reaching $10.90. 100,704 shares of the company's stock were exchanged, compared to its average volume of 547,910. AVANOS MEDICAL has a one year low of $9.30 and a one year high of $23.68. The company has a current ratio of 2.64, a quick ratio of 1.58 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $505.76 million, a PE ratio of -1.08 and a beta of 1.15. The firm has a fifty day moving average price of $11.59 and a two-hundred day moving average price of $12.11.
AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%.The business had revenue of $175.00 million for the quarter, compared to the consensus estimate of $165.50 million. During the same period in the previous year, the firm earned $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. As a group, equities research analysts forecast that AVANOS MEDICAL will post 1.32 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Gary Blackford purchased 40,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were purchased at an average cost of $10.99 per share, with a total value of $439,600.00. Following the completion of the acquisition, the director owned 40,000 shares in the company, valued at $439,600. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.64% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On AVANOS MEDICAL
Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its stake in AVANOS MEDICAL by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after purchasing an additional 2,307 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in AVANOS MEDICAL by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock valued at $77,000 after purchasing an additional 5,083 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in AVANOS MEDICAL in the second quarter valued at approximately $126,000. State of Wyoming raised its stake in AVANOS MEDICAL by 104.6% in the first quarter. State of Wyoming now owns 10,508 shares of the company's stock valued at $151,000 after purchasing an additional 5,371 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in AVANOS MEDICAL in the first quarter valued at approximately $181,000. 95.17% of the stock is owned by hedge funds and other institutional investors.
AVANOS MEDICAL Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.